v3.26.1
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 05, 2026
Jul. 17, 2024
Apr. 30, 2026
Mar. 31, 2026
Feb. 28, 2025
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Product Information [Line Items]                    
Amount annually to maintain operating activities           $ (429,861) $ (455,198)      
Number of warrants issued       7,950,000 6,250,000 7,950,000        
Cash on hand       $ 2,525,782   $ 2,525,782   $ 1,558,525    
Inventory       $ 56,863   56,863   57,257    
Research and development costs           $ 37,923 $ 119,281      
Intellectual Property [Member]                    
Product Information [Line Items]                    
Finite lived intangible asset useful life       10 years   10 years        
Finite lived intangible asset amortization period       10 years   10 years        
Maximum [Member]                    
Product Information [Line Items]                    
Property, Plant, and Equipment, Useful Life       5 years   5 years        
Subsequent Event [Member]                    
Product Information [Line Items]                    
Number of warrants issued     2,800,000              
Regulation A+ Offerings [Member]                    
Product Information [Line Items]                    
Value of shares issuable   $ 60,000,000                
Sale of stock value $ 75,000,000.0                  
Number of common stock shares issued, value       $ 2,203,800       $ 1,500,000 $ 2,266,000 $ 1,179,245
Number of common stock shares issued, shares       27,200,000 12,500,000     12,500,000 24,950,000 16,132,000
Regulation A+ Offerings [Member] | Subsequent Event [Member]                    
Product Information [Line Items]                    
Number of common stock shares issued, value     $ 2,203,800              
Number of common stock shares issued, shares     27,200,000              
Private Placement [Member]                    
Product Information [Line Items]                    
Number of warrants issued       27,800,000   27,800,000   6,250,000   18,797,000
Value of warrants issued               $ 6,250    
Private Placement [Member] | Subsequent Event [Member]                    
Product Information [Line Items]                    
Number of warrants issued     27,800,000              
Brachytherapy Product Line [Member]                    
Product Information [Line Items]                    
Amount annually to maintain operating activities           $ 3,000,000        
Radionuclide Therapy Product Line [Member]                    
Product Information [Line Items]                    
Amount annually to maintain operating activities           $ 3,000,000.0        
Offering term           Over the next 36 months, the Company believes it will require approximately $9.0 million in additional capital to: (i) fund the FDA approval process to conduct human clinical trials; (ii) conduct Phase I, pilot, clinical trials; (iii) activate several regional clinics to administer IsoPet® across the U.S.; (iv) create an independent production center within the current production site to create a template for future international manufacturing; and (v) initiate regulatory approval processes outside of the U.S.